While studies in CBF AML as a whole also do not demonstrate a prognostic significance of KIT mutations, such mutations within the t(8;21) subgroup of AML increase the risk of relapse and lead to an inferior OS of only 50% at 4 years [22, 26]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.